• Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:12012; TPM3; Name(s)=TPM3-ROS1 (DOI=10.1158/1538-7445.AM2020-3003; PubMed=36101520).
  

PubMed=29636358; DOI=10.1158/1078-0432.CCR-17-2452; PMCID=PMC6050099
Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth L. Jones, Laura Schubert, Andrea E. Doak, Adriana Estrada-Bernal, Kurtis D. Davies, Daniel T. Merrick, Paul A. Bunn Jr., W. Tom Purcell ...Show all 16 authors... , Rafal Dziadziuszko, Marileila Varella-Garcia, Dara L. Aisner, David Ross Camidge, Robert C. Doebele; Show fewer authors
Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer.
Clin. Cancer Res. 24:3334-3347(2018)

DOI=10.1158/1538-7445.AM2020-3003
Logan C. Tyler, Anh T. Le, Hala Nijmeh, Robert C. Doebele;
MET mediates entrectinib resistance in ROS1 gene fusion positive NSCLC.
Cancer Res. 80 Suppl. 16:3003-3003(2020)

DOI=10.1158/1535-7163.TARG-21-P076
Logan C. Tyler, Anh T. Le, Hala Nijmeh, Li-Ming Bao, Kristen M. Turner, Jason Christiansen, Robert C. Doebele;
Novel mechanisms of acquired TKI resistance in ROS1+ NSCLC.
Mol. Cancer Ther. 20 Suppl. 12:P076-P076(2021)

PubMed=36101520; DOI=10.1111/1759-7714.14656; PMCID=PMC9626307
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Li-Ming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla ...Show all 14 authors... , Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele; Show fewer authors
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Thorac. Cancer 13:3032-3041(2022)

DOI=10.63028/10067/2105480151162165141
Marc Terrones;
Profiling targeted therapy responses in ROS1+ non-small cell lung cancer using genomically engineered patient-derived cell lines.
Thesis PhD (2024); University of Antwerp; Antwerp; Belgium